Dosage of dabigatran as a risk factor for bleeding in atrial fibrillation

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1244-1245

  Liu, Siyao ^a   Kim, Cherub O ^a   Lucyk, Scott N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; WARFARIN;

ATRIAL FIBRILLATION; BLEEDING; CLINICAL TRIAL (TOPIC); HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FEMALE; MALE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 84937501261     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1286     Document Type: Letter

References (5)

1. Hernandez I, Baik SH, Pi?era A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18-24.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
3. Pradaxa (dabigatran etexilate mesylate) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2014.
4. Online L. Geriatric Lexi-Drugs. Hudson, OH: Lexi-Comp Inc; 2014, http://www.wolterskluwercdi.com/lexicomp-online/databases/. Accessed May 26, 2015.
5. Steinberg BA, Holmes DN, Piccini JP, et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J AmHeart Assoc. 2013;2(6):e000535.